Can a targeted drug boost standard chemo for a rare blood cancer?
NCT ID NCT04626791
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests whether adding acalabrutinib—a targeted drug that blocks a key enzyme in cancer cells—to a standard chemotherapy cocktail (modified VR-CAP) can improve outcomes for people with mantle cell lymphoma who are eligible for a stem cell transplant. The study enrolls adults aged 18–75 who have not received prior treatment. The goal is to see if the combination leads to a complete metabolic response, meaning no signs of active cancer after therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone, cytarabine) plus acalabrutinib
- What this could lead to
- If successful, this combination could become a more effective first-line therapy for mantle cell lymphoma, potentially improving complete response rates before transplant.
- What could go wrong
- This is a small Phase II trial, so results may not generalize. Adding acalabrutinib to chemotherapy may increase side effects like bleeding, infection, or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
University of Washington Medical Center - Montlake
Seattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-Drug attack aims to outsmart mantle cell lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers
- New drug combo aims to outsmart Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers